- Home
- CNTB vs CRBP Comparison
CNTB vs CRBP Comparison
Compare CNTB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | CRBP |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 134.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNTB | CRBP |
|---|---|---|
| Price | $2.62 | $8.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $8.50 | ★ $46.17 |
| AVG Volume (30 Days) | 99.4K | ★ 144.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.22 | 64.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,033,000.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24,617.69 | $220.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $0.51 | $4.64 |
| 52 Week High | $3.28 | $20.56 |
Technical Indicators
Market Signals| Indicator | CNTB | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 56.49 |
| Support Level | $2.09 | $8.39 |
| Resistance Level | $2.86 | $9.51 |
| Average True Range (ATR) | 0.23 | 0.48 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 31.25 | 82.89 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.